This four day program is divided into a two-day symposium with lectures presented by world class scientists in the field of immuno-oncology and with representation by all the main multiplex [….]
Pharma, biotech and the drug delivery industries gather annually at PODD to assess delivery needs, latest trends and information on deals and learn about a wide range of innovative drug [….]
What’s up, everybody? My name’s Jake Greenwood and if you’re not aware, I have a weekly segment on LinkedIn called #WannaGoWednesday where I highlight upcoming Life Sciences Industry events in the BioHealth Capital Region and beyond. Very often I’m looking at BioBuzz to see what those upcoming events might be. Well, the good folks leading the community at BioBuzz have invited me to invade their platform and share the can’t miss events for the remainder of 2021.
Johns Hopkins Technology Ventures (JHTV) has had a significant impact on the Maryland life sciences ecosystem since its founding in 2014, assisting with hundreds of licensed therapeutics in development and backing nearly 200 startups that have collectively nearly $3 billion in venture capital funding, 30% of which has remained in the state.
AstraZeneca is reportedly in talks to shift production of its coronavirus vaccine to a Maryland-based factory operated by Catalent, Inc.
Maryland’s reputation as the destination state for biotech jobs and life science research continues to climb as new startups emerge across its biohealth cluster regions.
Raphaella Thorson is an R&D Learning Technology Leader at AstraZeneca. She has been in her new role since November 2020 focusing on how to leverage AZ learning technologies to maintain training inspection readiness across R&D. Raphaella is a mother of 3 and In her spare time she likes to spend time with her family and friends, as well as travel to anywhere with a beautiful beach. She is a huge music fan and enjoys listening to anything from Classical music to Metal.
Novavax trials highlight Maryland’s COVID-fighting complex When Novavax Inc. received $1.6 billion last year from the federal government to speed up testing and production of a coronavirus vaccine, some observers [….]
When AstraZeneca (AZ) announced in 2019 that it was officially retiring the MedImmune brand, questions naturally arose about whether the U.K. pharma giant would continue the legacy MedImmune support for the BioHealth Capital Region’s (BHCR) life science ecosystem.
2020 is over, but its impact on how employers recruit and hire talent will reverberate for years to come.